NICARDIPINE HYDROCHLORIDE

Post-LOE

nicardipine hydrochloride

Chiesi

ANDAORALCAPSULE

Approved

Jul 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

NICARDIPINE HYDROCHLORIDE (nicardipine hydrochloride) by Chiesi is mechanism of action nicardipine hydrochloride capsules are a calcium entry blocker (slow channel blocker or calcium ion antagonist) that inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle without changing serum calcium concentrations. Approved for hypertension, hypertension. First approved in 2023.

Drug data last refreshed 21h ago

Mechanism of Action

Mechanism of Action Nicardipine hydrochloride capsules are a calcium entry blocker (slow channel blocker or calcium ion antagonist) that inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle without changing serum calcium concentrations. The contractile processes…

Indications (1)

hypertension

Company

Worked on NICARDIPINE HYDROCHLORIDE at Chiesi? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.